DDInter16 DDInter1397
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) upregulates {v} (Gene) HSD17B10
HSD17B10 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) causes {v} (Side Effect) Muscle spasms
Muscle spasms {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) downregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Fosphenytoin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rasagiline
Rasagiline {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) downregulates {v} (Gene) KIF2C
KIF2C {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Paroxetine (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) upregulates HSD17B10 (Gene) and HSD17B10 (Gene) is downregulated by Paroxetine (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Paroxetine (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) downregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Paroxetine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Rasagiline and Rasagiline (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Paroxetine (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) downregulates KIF2C (Gene) and KIF2C (Gene) is downregulated by Paroxetine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Paroxetine (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Paroxetine (Compound)